according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 6.1 09/30/2023 679941-00019 Date of first issue: 05/19/2016

SECTION 1. IDENTIFICATION

Product name Daptomycin Injection Formulation - 2nd Generation

Manufacturer or supplier's details

Company name of supplier Merck & Co., Inc

Address 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone 908-740-4000 Emergency telephone 1-908-423-6000

E-mail address EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Pharmaceutical Recommended use Restrictions on use Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

- repeated exposure

(Dermal)

Specific target organ toxicity : Category 2 (muscle, Kidney, Nervous system)

GHS label elements

Hazard pictograms



Signal Word Warning

Hazard Statements If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H373 May cause damage to organs (muscle, Kidney, Nervous system) through prolonged or repeated exposure in contact with

skin.

Precautionary Statements Prevention:

P260 Do not breathe dust.

Response:

P314 Get medical attention if you feel unwell.

Disposal:

P501 Dispose of contents and container to an approved waste

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 50 - < 70
Daptomycin	103060-53-3	>= 30 - < 50

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

May cause damage to organs through prolonged or repeated

Most important symptoms and effects, both acute and

exposure in contact with skin.

delayed

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

Specific hazards during fire

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not get on skin or clothing.

Do not get on skin or cic

Do not breathe dust.

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m³

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m³

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

ticulates

10 mg/m³

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

 5 mg/m^3

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
		exposure)	concentration	
Sucrose	57-50-1	TWA	10 mg/m ³	ACGIH
		TWA (Res-	5 mg/m³	NIOSH REL
		pirable)		
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total	15 mg/m³	OSHA Z-1

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

		dust)		
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Daptomycin	103060-53-3	TWA	800 μg/m3 (OEB 2)	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : lyophilized cake

Color : light brown

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 6.1 09/30/2023 679941-00019 Date of first issue: 05/19/2016

Odor : No data available

Odor Threshold : No data available

pH : 6.5 - 7.3

(as aqueous solution)

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Daptomycin:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Daptomycin:

Species : Rabbit

Result : Mild eye irritation

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Sucrose:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Daptomycin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Hamster

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Daptomycin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 150 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 75 mg/kg body weight Result: No significant adverse effects were reported

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 75 mg/kg body weight Result: No significant adverse effects were reported

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (muscle, Kidney, Nervous system) through prolonged or repeated exposure in contact with skin.

Components:

Daptomycin:

Target Organs : muscle, Kidney, Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Daptomycin:

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 40 mg/kg
Application Route : Intravenous
Exposure time : 3 Months

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

Target Organs : Skeletal muscle

Species : Monkey
NOAEL : 10 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Species : Dog

Application Route : Intravenous Exposure time : 28 Days

Target Organs : Skeletal muscle, Nervous system

Symptoms : muscle twitching

Species : Juvenile dog LOAEL : 50 mg/kg Application Route : Intravenous Exposure time : 28 Days

Target Organs : Skeletal muscle, Nervous system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Daptomycin:

General Information : Symptoms: Rash, Diarrhea, vaginitis

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Sucrose:

Partition coefficient: n- : Pow: < 1

octanol/water

Mobility in soil

No data available

Other adverse effects

No data available

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

US State Regulations

Pennsylvania Right To Know

Sucrose 57-50-1 Daptomycin 103060-53-3

California Permissible Exposure Limits for Chemical Contaminants

Sucrose 57-50-1

The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



Special hazard

HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

according to the OSHA Hazard Communication Standard



Daptomycin Injection Formulation - 2nd Generation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 679941-00019 Date of first issue: 05/19/2016

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8